
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59.
The company reported sales of $3.75 billion, up 1% year over year, beating the consensus of $3.59 billion.